Showing results (201-210 of 374) with videos related to
Sort By:
Pageof 38
International Journal of Methods in Psychiatric Research|August 28, 2010
The Computerised Manchester Child Attachment Story Task: a novel medium for assessing attachment patternsHelen Minnis, Warren Read, Brenda Connolly, et al.Developmental Medicine and Child Neurology|November 21, 2012
Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based studyShruti Garg, Annukka Lehtonen, Susan M Huson, et al.Autism Research : Official Journal of the International Society for Autism Research|June 28, 2024
Parent-infant interaction trajectories in infants with an elevated likelihood for autism in relation to 3-year clinical outcomeEirini Papageorgopoulou, Emily J H Jones, Mark H Johnson, et al.Journal of Pediatric Surgery|November 3, 2019
Toy Guns, Real Danger: An Update on Pediatric Injury Patterns Related to Nonpowder WeaponsRobert J McLoughlin, Alyssa Stetson, Jonathan Green, et al.Frontiers in Psychology|December 28, 2020
Can Psychodynamically Oriented Early Prevention for "Children-at-Risk" in Urban Areas With High Social Problem Density Strengthen Their Developmental Potential? A Cluster Randomized Trial of Two Kindergarten-Based Prevention ProgramsTamara Fischmann, Lorena K Asseburg, Jonathan Green, et al.Journal of Neurodevelopmental Disorders|August 23, 2023
Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memorySamantha J Booth, Shruti Garg, Laura J E Brown, et al.Pediatrics|November 6, 2013
Neurofibromatosis type 1 and autism spectrum disorderShruti Garg, Jonathan Green, Kathy Leadbitter, et al.The American Journal of Emergency Medicine|June 10, 2018
The risk of snow sport injury in pediatric patientsRobert J McLoughlin, Jonathan Green, Pradeep P Nazarey, et al.Molecular Autism|December 6, 2017
Early development of infants with neurofibromatosis type 1: a case seriesAnna May Kolesnik, Emily Jane Harrison Jones, Shruti Garg, et al.JAMA Oncology|January 27, 2017
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical TrialGabriel N Hortobagyi, Catherine Van Poznak, W Graydon Harker, et al.Pageof 38